Drug and Therapeutics Committee – Minutes – Unconfirmed

Date / Time	Thursday 12th August 2021 8:15am – 9:30am
Venue	Webex
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Dr H Klonin, Consultant Paediatrician, HUTH Mr R Kapur, Vascular Surgeon, HUTH Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Ms J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr A Samson, Consultant Infectious Diseases, HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH
Apologies	Mr P O'Brien, Deputy Chief Pharmacist, HUTH Mr D Corral, Chief Pharmacist, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.08.01	**Apologies**	As above					
2021.08.02	**Declarations of Interest**	None					
2021.08.03	**Minutes of the previous meeting**	Accepted as a true record with the following amendments Pg 7 add "it was agreed the final decision lay with HERPC and the CCG committees" and alter spelling of discuss. The committee then discussed the Biologics and Small Molecules in Inflammatory Bowel Disease guideline that had been on last meetings agenda and ask what the outcome was. AM explained the document had been escalated to OQC who had referred to surgical governance. This meeting was taking place at the same time as D&T and so the outcome was as yet unknown. Many members of the committee were keen to know the outcome of the discussions but AM said it was best to park this issue for now until further information becomes available.	Approved pending amendments Noted	WH to amend		9/21	
2021.08.04	**Action Tracker**	**Tracker** JM has discussed circulating Levosimendan information with POB, but email has still not been circulated to pharmacists so JM said she would discuss with POB again **NICE Guidance** JM to discuss with Dr Zaman TA681 Baricitinib for treating moderate to severe atopic dermatitis. JM said she would chase Dr Zaman again. **Tracker** AM has written to ED paediatricians regarding intranasal analgesia guideline **Tracker** HK emailed ED paediatricians regarding intranasal analgesia guideline but has had no response. JM agreed to forward the document to HK who will raise at paediatric governance	JM to discuss with POB JM to chase Dr Zaman Action complete JM to send to HK who will add to paediatric	 No further action Discuss at paediatric governance	JM JM AM JM HK		8/21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
			governance agenda				
		Dissemination of Information Across All Healthcare Groups /Providers DC/JM to invite comms team representative to next meeting NEW ACTION : JM discussed with SG who is happy to trial with heath group pharmacists going through speciality governance/clinical meetings for 6 months.	Action complete	No further action	JM		8/21
		AOB JM has sent trust warfarin procedure to RK and SR	Action complete	No further action	JM		8/21
		New Product Requests AM has written to applicants and WH has updated the formulary	Action complete	No further action	AM		8/21
		New Product Requests JM has discuss high dose cyanocobalamin with the DME consultants and Dr Allsup who all agreed that there are many patients receiving injections who should be prescribed the oral preparation this was also discussed at HERPC	Action complete	No further action	JM		8/21
		New Product Requests JM has requested HERPC management of vitamin B12 and folate deficiency anaemia guideline be updated	Action complete	No further action	JM		8/21
		NICE guidelines TA 696 WH has altered tafamidis entry on formulary and JM told the committee there were only two patients currently receiving treatment.	Action complete	No further action	WH		8/21
		NICE guidelines TA 697 – AM has written to thrombosis committee and suggest updating guidance to include Andexanet alfa, thrombosis committee are now considering this	Action complete	No further action	AM		8/21
		NICE Guidelines					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		TA 698 Ravulizumab – JM checked and Leeds is the specialist centre for this treatment so will add to back of formulary and annotate with this. **Clinical Guidelines** The Biologics and Small Molecules in Inflammatory Bowel Disease Guideline was discussed at OQC who have referred it to surgery governance. **Clinical Guidelines** WH to add Type 2 Diabetes (HERPC Guideline) to the HERPC agenda **Clinical Guidelines** JM has informed author of Guideline for Opioid Prescribing in Acute Pain Management that it is approved **Correspondence Received** Project Orbis – JM has informed Sarah Scargill of committees decision **AOB** JM has discussed D&T with infectious disease pharmacist once Dr Samson takes up her secondment .	WH to add to annotate back of formulary Action complete Action complete Action complete Action complete	Formulary to be updated No further action No further action No further action No further action	WH DC WH JM JM JM		 8/21 8/21 8/21 8/21
2021.08.05	**New Product Requests**	**New Product Requests** Selpercatinib – Cancer – Dr Upadhyay Although application has not been signed JM said she has discussed with Prof. Patmore who is happy to support the application. Selpercatinib will be available by a company FOC scheme, who have agreed to continue supply to existing patients should NICE reject it. Selpercatinib has not as yet been NICE approved. ML said he had seen the evidence for treatment of lung cancer which was not strong and was only available for phase II, however the response rate was 30% compared with 8% for docetaxel. ML said he felt it would be wise to wait for the phase III study to be published before making a decision. AM suggested it would therefore be better to make available on an	Available via chairs approval only until further evidence obtained	AM to write to applicant	AM	9/21	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		individual basis via ad hominum approval and await the phase III results, the committee agreed with this decision. **ARIA Forms** • TA695 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma	 Approved	WH to add to formulary	WH	9/21	
2021.08.06	**NICE Guidance**	**Nice Guidance** **June 2021** • TA705 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer • TA 706 Ozanimod for treating relapsing–remitting multiple sclerosis (Not recommended) • TA 707 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer • TA708 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis Budesonide is on formulary already but not this preparation. The committee discussed the way forward and agreed as this recommendation was for inducing remission not maintenance it should be made red for this indication to keep prescribing in house. • TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency • TA710 Ravulizumab for treating atypical haemolytic uraemic syndrome • TA711 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs • CG138 Patient experience in adult NHS services: improving the experience of care for people using adult NHS services • CG142 Autism spectrum disorder in adults: diagnosis and management	 On formulary Not recommended On formulary Add to HERPC agenda for traffic light discussion. AM to write to gastro with D&T approval for use in line with NICE On formulary Specialist centre is at Newcastle On formulary Noted Noted Noted	 Noted Noted Noted WH to add to HERPC agenda AM to write to gastro Noted WH to update formulary Noted	 WH AM WH	 9/21 9/21 9/21	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		• CG170 Autism spectrum disorder in under 19s: support and management • NG191 COVID-19 rapid guideline: managing COVID-19 Updated to include advice not to prescribe azithromycin and alter dose for prednisolone • NG196 Atrial fibrillation: diagnosis and management • NG197 Shared decision making • NG198 Acne vulgaris: management New guideline which contains some non formulary items but this is not an issue as they are only recommendations to use. **July 2021** • TA249 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation • TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation • TA275 Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation • TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation • TA712 Enzalutamide for treating hormone-sensitive metastatic prostate cancer • TA713 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy • TA714 Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) • TA715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed • TA717 Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) • TA718 Ixekizumab for treating axial spondyloarthritis	Noted Noted Noted Noted – all DOAC TA have been updated to contain information on all DOACs On formulary On formulary Terminated Rheumatology pharmacist is working on updating pathway Terminated On formulary				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		• TA719 Secukinumab for treating non-radiographic axial spondyloarthritis • NG199 Clostridioides difficile infection: antimicrobial prescribing • NG200 COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT)	On formulary Trust guideline to be updated JM to update webpage	JM to update guideline and webpage	JM	9/21	
2021.08.07	**MHRA Drug Safety Update**	**June 21** CDK 4/6 Inhibitors (abemaciclib palbociclib ribociclib) reports of interstitial lung disease and pneumonitis including severe cases Atezolizumab (Tecentriq) and other immune stimulatory anti cancer drugs : risk of severe cutaneous adverse reactions (SCARs) Covid 19 Vaccines Update **July 21** Chloramphenicol eye drops containing borax or boric acid buffers : Use in children younger than 2 years Herbal and homeopathic medicines : reminder to be vigilant to for suspect adverse events and to report them to the yellow card system Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin)temporary monitoring advice during coronavirus pandemic Covid 19 Vaccines Update	Noted ML to check relevant consultants are aware Noted		ML	9/21	
2021.08.08	**Minutes SMPC**	May 21	Noted				8/21
2021.08.09	**Minutes from HERPC**	May 21	Noted				8/21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.08.10	**Regional Medicines Optimisation Committees**	• SCF Protocol Draft Consultation 3 • SCF Protocol Draft Consultation 4 In relation to SCF AM said he had received a verbal complaint regarding ophthalmology not performing recommended yearly eye assessments, JM and OO agreed to discuss further outside of meeting and give an update next time.	JM will email relevant trust consultant to inform them of the drafts		JM	9/21	
2021.08.11	**Clinical Guidelines**	• Remdesivir • Tocilizumab	Approved	JM to inform authors of committees decision	JM	9/21	
2021.08.12	**Filgotinib Review**	WH had reviewed the pharmacy dispensing systems and found that since its approval earlier this year there had only been one patient prescribed Filgotinib	Noted	No further action			8/21
2021.08.13	**Melatonin Formulation Review**	Dr Jose had requested that a different brand of Melatonin Slenyto be added to formulary as it was licensed for use in 2-18yr olds alongside Circadin. This led JM to review current licensed melatonin preparations. The use of Slenyto raised several issues as Circadin is not licensed in this age group but Slenyto is. Melatonin is a big part of the CCG spend on under 19s and switching to a more costly product would have a large financial impact on the CCG budget. Slenyto are smaller tablets and therefore improve compliance in younger children, but Circadin can be crushed	Committee agreed that the SCF should be reviewed at HERPC	JM to update SCF and WH to add to HERPC agenda	JM WH	9/21	
2021.08.14	**Correspondence received**	None					8/21
2021.08.15	**Chairs approvals**	None					8/21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.08.16	**Issues to escalate to OQC**	**None**					8/21
2021.08.17	**Any Other Business**	AM said that he had been approached by Professor Sathyapalan who would like to sit as a member of the committee, the committee approved this decision and agreed it would be good to have an endocrinologist as a member JM said that a different salt of the phosphate oral solution had been added to the unlicensed list as the previously used preparation was currently unavailable this was for treatment of patients on NICU AM raised issues with hydroxychloroquine and compliance with monitoring. JM and OO to meet outside D&T to discuss way forward with rheumatology and ophthalmology.	AM to write to Professor Sathyapalan and invite him to join the committee Noted JM/OO to meet	JM to arrange meeting	JM	10/21	
	Date and Time of Next Meeting	**Date: Thursday 8th July 2021** **Time: 8.15am-9.30am** **Venue: WEBEX**					